As transporters including SLC7A5 also transport Kyn, they can contribute further to its influx into tumours, thereby bypassing IDO, TDO and FAMID, activating the AhR, further enhancing IDO expression, and undermining invading T-cell function [96,136]. Here, SLC7A5 is linked to neoplasm.